Biotech Values

[biocrio]

*What they did was provide a conceptual look that has the buzzwords that they feel will attract investors. VEGF, angiogenesis, apoptosis etc..*

"buzzwords"? What other words would you have prefered they use? Those are the correct words to use to complete the description, at hand. VEGF, angiogenesis, apoptosis? I suppose every company in the field of angiogenesis or one whose compound makes an attempt at achieving programed cell death as its MO but alternatively uses the word "apoptosis" to describe its MO, is using "buzz words" instead of the PROPER WORD? You call these "buzz words"? I'm sorry but you have lost me and my willingness to discuss this issue with you, FOR OBVIOUS REASONS. Yes, I'm sure their >primary< goal or desired accomplishment when scripting Evizon's MO was to attract investors. Funny.

*Again, I see nothing in Genara's presentation of its MOA that is more or less explicit than other companies trying to retrofit an MOA to a previously existing compound.*

O.K., so Genr is pretty much a part of what you would refer to as the group >standard< when refering to the language and intensity of description Genr uses to describe their compounds MOA in their presentation. So what makes them stand out so much if, as you say, they provide "no more or less" than the rest of the companies you refer to?, What previously existing compound do you claim Genr is retrofiting Evizon's MOA into?---biocrio